Research on USA and EU Regulations of Post-approval Drug Manufacturing Changes

Abstract

Abstract: Objective To put forward some suggestions on post-approval drug manufacturing changes for our country. Methods The USA and EU regulations of post-approval drug manufacturing changes were studied, and our deficiencies on post-approval drug manufacturing changes were analyzed. Results Both USA and EMA classify manufacturing changes based on risks, pay more attention to supervision of changes with high risks, and use post-approval change management protocol to give manufacturers who understand the risks of their products with more flexibility. Conclusion We should apply the risk-based approach to drug manufacturing changes to substitute the present unified regulatory way, thereby alleviate the burden of CFDA and corporations, and use post-approval change management protocol to increase more flexibility on manufacturing changes and promote manufacturs^, continuous improvement and innovation.

Key words: drug manufacturing change, risk-based approach, post-approval change management protocol

CLC Number:

R954

LI Xiao-yu, CHAI Qian-wen, TIAN De-long, YANG Yue. Research on USA and EU Regulations of Post-approval Drug Manufacturing Changes[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 476-481.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2016/V13/I8/476

References

[1] ICH.GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q7(Current Step 4version )[S/OL].(2000-11-10)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/ Step4/Q7_Guideline.pdf.
[2] ICH.PHARMACEUTICAL QUALITY SYSTEM Q10 (Current Step 4 version ) [S/OL].(2008-06-04)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf.
[3] ICH. Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management[EB/OL].(2014-07-28)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_Paper_July_2014.pdf.
[4] EMA. COMMISSION REGULATION (EC) No 1234/2008of concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products [S/OL]. (2008-11-24)[2016-06-14].http://ec.europa.eu/health/files/eudralex/vol-1/reg_2008_1234_cons_2012-11-02/reg_2008_1234_cons_2012-11-02_en.pdf.
[5] USA.21 USC 356a: Manufacturing changes[S/OL]. (2016-01-30) [2016-06-14].http://uscode.house.govviewxhtml?req=granuleid:USC-prelim-title21-section356a&num=0&edition=prelim.
[6] FDA.CODEOF FEDERAL REGULATIONSTITLE 21 314.70(10) [S/OL].(2014-01-01)[2016-06-14].http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5.pdf.
[7] EMA. Guidelines on the details of the various categories of variations,on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures[S/OL].（2013-02-08）[2016-06-14].http://ec.europa.eu/health/files/eudralex/vol-1/c_2013_223/c_2013_2804_en.pdf.
[8] FDA. North Bethesda, MD. Supplement Review Process 2012 GPhA/FDA Fall Technical Conference[EB/OL]. (2012-10-03) [2016-06-14].http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm368222.pdf.
[9] FDA. Guidance for Industry CMC Post-approval Manufacturing Changes To Be Documented in Annual Reports [S/OL]. (2014-03)[2016-06-14].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM217043.pdf.
[10] EMA. Industry European Workshop on Lifecycle Management Application Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols[EB/OL] .(2015-11-17)[2016-06-14].http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2015/11/WC500196662.pdf.
[11] ICH. Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management[S/OL]. (2014-07-28)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_Paper_July_2014.pdf.
[12] EMA.Questions and answers on post approval change management protocols[S/OL] .(2012-03-30)[2016-06-14].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/04/WC500125400.pdf.
[13] FDA.Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information Guidance for Industry DRAFT GUIDANCE[S/OL].（2016-04）[2016-06-14].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm496611.pdf.
[14] FDA.GPhA Fall Technical Conference.QbD Status Update Generic Drugs[EB/OL] .(2011-10-03)[2016-06-14].http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelope-dandapproved/approvalapplications/abbreviatednewdrugapplicatio-nandagenerics/ucm292666.pdf.
[15] 北京大学药物信息与工程研究中心翻译.药品注册批准前检查—美国药品监管法规核心理念概述（第2版）[M].北京：北京大学医学出版社,2011：15-16.
[16] 吴晓明,郑强. 原料药产地变更对药品质量的影响[J]. 中国新药杂志,2014,23（12）:1382-1389.
[17] CFDA.总局关于辽宁玉皇药业有限公司哈高科白天鹅药业集团有限公司违法生产注射用促肝细胞生长素的通告[EB/OL].(2016-03-15)[2016-06-14]. http://www.sda.gov.cn/WS01/CL0087/147198.html.
[18] CFDA.国家食品药品监督管理总局关于停止进口脑蛋白水解物注射液等4个药品的公告（2016年第13号）[EB/OL].(2016-01-22)[2016-06-14].http://www.sda.gov.cn/WS01/CL0087/142820.html.
[19] CFDA.国家食品药品监督管理总局药品审评中心2015年度药品审评报告[EB/OL].（2016-03-03）(2016-06-14). http://www.cde.org.cn/news.do?method=viewInfoCommon&id=313528.
[20] CFDA.（国产）药品补充申请审[EB/OL].(2006-02-20)[2016-06-14]. http://www.sda.gov.cn/WS01/CL0372/24058.html.
[21] CFDA.进口(含港、澳、台)药品补充申请审核[EB/OL].(2012-11-05)[2016-06-14].http://www.sda.gov.cn/WS01/CL0371/76181.html.
[22] CFDA.（国产）直接接触药品的包装材料和容器补充申请审核[EB/OL].(2006-02-20)[2016-06-14]. http://www.sda.gov.cn/WS01/CL0372/24070.html.